|
|
Article: Biologic resolves all severities of psoriatic arthritis.(Skin Disorders)(tumor necrosis factor blocker adalimumab)(Brief article)
- Article from:
- Family Practice News
- Article date:
- April 15, 2006
- Author:
CopyrightCOPYRIGHT 2006 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
San Francisco -- Adalimumab is effective in treating both mild to moderate and moderate to severe skin disease in patients who have psoriatic arthritis, Dr. Dafna D. Gladman reported in a poster presentation at the annual meeting of the American Academy of Dermatology.
Adalimumab, a tumor necrosis factor blocker, was approved by the Food and Drug Administration in 2005 for the treatment of rheumatoid arthritis and psoriatic arthritis.
To assess whether the severity of skin disease affected the response of psoriasis to the drug, Dr. Gladman and her associates per formed a post hoc analysis of a 24-week, placebo-controlled phase III trial involving ...